Pulmonary extraction and accumulation of lipid formulations of amphotericin B
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (7) , 2528-2532
- https://doi.org/10.1097/00003246-200007000-00056
Abstract
To compare single-dose first pass uptake and accumulation of conventional amphotericin B (cAmB), liposomal amphotericin B (L-AmB), and amphotericin B lipid complex (ABLC) by the intact feline lungs. Prospective, controlled animal study. Experimental laboratory in a university teaching hospital. A total of 31 spontaneously breathing, anesthetized cats. The pulmonary uptake of cAmB, L-AmB, and ABLC during a single passage through the pulmonary circulation, and the pulmonary retention of these drugs were studied after a bolus [cAmB, L-AmB, and ABLC, 1 mg/kg (n = 9 each) and ABLC, 5 mg/kg (n = 4)] administration into the right ventricle. The amount of drug taken up by the lung during the first pass was measured from double indicator-dilution outflow curves. Animals were killed 30 mins (cAmB, n = 4; L-AmB, n = 4), 1 hr (cAmB, n = 5; L-AmB, n = 5; ABLC, n = 5), or 6 hrs (ABLC, 1 mg/kg, n = 4; 5 mg/kg, n = 4) after drug administration. The first-pass uptake of cAmB, L-AmB, and ABLC (mean ± sd) by the lung was 73% ± 5%, 69% ± 8%, and 82% ± 6% of the injected dose (1 mg/kg), respectively (p > .05). ABLC (1 mg/kg) exhibited prolonged retention in the lung; 23% and 15% of the injected dose of ABLC remained in the lung 1 hr and 6 hrs after its administration, respectively. In contrast, cAmB and L-AmB exhibited rapid back diffusion of the drug out of the lung. After 30 mins, only 4% of the administered cAmB and L-AmB remained in the lung and after 1 hr only 1% to 2% was retained. Increasing the dose of ABLC from 1 mg/kg to 5 mg/kg did not alter pulmonary extraction of the drug; however, compared with the lower dose (1 mg/kg), higher concentrations of the drug were found in the lung 6 hrs after its administration. The results demonstrate a substantial extraction and accumulation of ABLC by the lung. This affinity for the lungs may have clinical implications for treating fungal infections that primarily involve the lung. Further studies are required to confirm the potential clinical relevance of these data.Keywords
This publication has 17 references indexed in Scilit:
- Amphotericin B Lipid ComplexAnnals of Pharmacotherapy, 1997
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996
- Differential cytology of bronchoalveolar lavage fluid in immunosuppressed children with pulmonary infiltrates.Archives of Disease in Childhood, 1996
- Lipid Formulations of Amphotericin B: Recent Progress and Future DirectionsClinical Infectious Diseases, 1996
- Rational design of amphiphile-based drug carriers and sterically stabilized carriersJournal of Liposome Research, 1995
- Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related ToxicitiesJournal of Liposome Research, 1993
- Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in miceAntimicrobial Agents and Chemotherapy, 1992
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990
- Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in miceAntimicrobial Agents and Chemotherapy, 1989
- Unusual lipid structures selectively reduce the toxicity of amphotericin B.Proceedings of the National Academy of Sciences, 1988